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EDITORIAL REVIEW
Host virus interactions and the molecular regulation of HIV- 1:
Role in the pathogenesis of HIV-associated nephropathy
Chronic renal disease affects up to 10% of children and adults
with HIV infection, and is manifested by a characteristic
syndrome that has been termed HIV-associated nephropathy
(HIVAN) [recently reviewed in 1—3]. The main histologic
features of this syndrome are shown in Figure 1 and include: (1)
focal segmental and global glomeruloscierosis with glomerular
capillary tuft collapse; (2) mesangial proliferation and visceral
epithelial cell hypertrophy; (3) microcystic tubular diltation,
with atrophy and degeneration of tubular epithelial cells; (4)
interstitial inflammation, with a predominantly mononuclear
cell infiltrate, and interstitial fibrosis; and (5) ultrastructural
evidence of tubuloreticular inclusions within glomerular endo-
thelial cells.
Epidemiological studies suggest that among HIV infected
patients, the risk for developing HIVAN is not uniformly
distributed. Most of the reported cases of HI VAN in the United
States have occurred in African American patients, both in
adults [4—6] and children [7, 8]. This would be consistent with
either an unidentified cofactor, more common within the Afri-
can American population, or a genetic predisposition, as may
be the case for other renal diseases such as hypertensive
nephrosclerosis. HIVAN also occurs in France, Brazil, and
Africa.
AIDS predisposes patients to a broad range of infection,
frequently with opportunistic organisms, and it has been pro-
posed that renal infection by opportunistic pathogens such as
cytomegalovirus (CMV) might participate in the pathogenesis
of HIVAN. Current evidence, however, suggests that CMV is
no more common in HIV patients with nephropathy than in
those without. The only evidence for a link between opportu-
nistic renal infection and HIVAN comes from the work of
Bauer et al, in which a novel strain of a rarely isolated human
Mycoplasma (Mycoplasma fermentans incognitus) has been
cultured from multiple organs of AIDS patients dying of an
acute influenza-like illness [9]. Antigens from this Mycoplasma
strain are present within mononuclear interstitial cells from
kidneys of HIVAN patients and are absent from renal tissue
obtained from AIDS patients without nephropathy. These data
suggest an association between opportunistic infection and
HIVAN but do not prove that these infections are etiologic in
its pathogenesis.
The contribution of immunologic factors to the pathogenesis
of HIVAN remains controversial. The typical case of HIVAN
lacks prominent immune deposits within the glomerulus, al-
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though segmental deposits of 1gM and C3 are seen in some
cases, and the prevalence of immune complex nephritis may be
somewhat higher in Europe [3]. Thus, it appears unlikely that
antibody-mediated glomerular injury plays a primary patho-
genic role. On the other hand, several groups have reported that
HIV-1 seropositive patients with mesangial proliferation, me-
sangial expansion and/or crescentic glomerulonephritis may
have glomerular IgA deposits [3, 10—12]. In two patients,
immune complexes eluted from glomeruli were shown to con-
tain p24 Gag protein, gp4l, and envelope glycoprotein [11].
Thus, IgA nephropathy may represent a small subgroup of
HIVAN in which immune complexes potentially play a patho-
genic role. While antibody-mediated glomerular injury does not
appear to be central to the disease process in most patients with
HIVAN, a role for cellular immunity has not been excluded.
Indeed, CD8+ T lymphocytes have been found within the renal
interstitium in patients with HIVAN [13, 14].
Many of the manifestations of HIV infection have been
thought previously to result from the consequences of immu-
nosuppression. HIVAN is similar to Kaposi's sarcoma (KS)
and AIDS-associated dementia in that it often presents in the
absence of overt immunodeficiency. Rather than dependence
upon immunosuppression, there is now increasing evidence
that replicating virus or viral proteins may directly induce renal
disease. What remains unclear is whether renal tissues sustain
a productive infection or, alternatively, whether virus or viral
proteins have deleterious effects upon renal tissues. Renal
exposure to virus or viral proteins could readily be accom-
plished by their presence in the circulation, by exposure of
renal tissues to infected inflammatory cells, or by the filtration
and reabsorption of viral proteins.
The presence of replicating HIV within renal tissues remains
a central but controversial issue. In support of viral replication
in renal cells, it has been reported that p24 Gag (viral capsid)
protein and viral nucleic acid are present in renal tubular
epithelial cells. Furthermore, viral nucleic acid has also been
found in glomerular parietal and visceral epithelial cells [15]. It
is unclear, however, that these proteins and nucleic acids are
the result of replicating virus in renal cells, or are wholly or, in
part, due to cellular uptake of circulating or filtered viral
proteins. Studies with cultured human glomerular cells have
indicated that the cloned HxB2 strain of HIV-1 can readily
infect glomerular endothelial cells [16]. Thus, it appears that
glomerular endothelial cells can sustain replicating virus in
vitro. The significance of this finding, however, is unclear when
viewed in the context of the apparent tissue distribution of viral
nucleic acids in patients with HIVAN (mainly epithelial).
Several observations appear to stand in opposition to the
hypothesis that viral replication occurs either in extrinsic in-
flammatory cells that invade the kidney or in primary renal
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Fig. 1. Histopathology of human HI VAN and of the HIV transgenic mouse. A. Kidney from a patient with HIVAN, showing an obsolescent
glomerulus (arrowhead), dilatated tubules occupied by proteinaceous casts (asterisk), and an area of interstitial fibrosis and mononuclear cell
infiltrate. B. Kidney from the same patient, showing segmental glomeruloscierosis and reactive glomerular epithelial cells. C. Kidney from HIV-l
transgenic mouse, with glomeruloscierosis (arrowhead) and dilated tubules, some of which contain proteinaceous casts (asterisk). D. Kidney from
HIV transgenic mouse, with segmental glomeruloscierosis and reactive glomerular epithelial cells. All slides stained with PAS; original
magnification: A, 50, B, 125, C, 50, and D, 200.
tissues. Several groups have failed to demonstrate HIV anti-
gens in kidney tissue obtained from patients with HIVAN [17,
18]. In situ hybridization studies have not shown HIV infected
lymphocytes or macrophages in kidneys of patients with
HIVAN. This method is relatively insensitive, however, and
the failure to detect viral nucleic acid may result from low levels
of viral replication and mRNA expression. PCR amplification
coupled with in situ localization may be necessary to demon-
strate the presence of HIV- 1 in mononuclear cells within
kidney, as suggested by a recent study with peripheral blood
mononuclear cells [19].
Kimmel et al microdissected kidney tissue obtained from
HIV seropositive patients with and without typical HI VAN and
performed DNA PCR. They report the presence of proviral
nucleic acid within glomeruli, tubules, and infiltrating intersti-
tial cells, but not within normal interstitial cells [20]. These data
may indicate that intact HIV provirus is present within renal
cells. Alternatively, these results could be due to contamination
by HI V-infected passenger lymphocytes within the glomerulus.
Further studies using techniques, such as in situ PCR amplifi-
cation, will be required to establish whether HIV-1 infects
intrinsic renal cells in vivo.
The issues of whether HIV-l infects intrinsic renal cells and
whether renal cells can sustain viral replication remain unset-
tled. It has been suggested that human glomerular tissue may
express CD4 [211, but if this is the case the cell that expresses
CD4 has not been determined. The expression of CD4 may not
be a requirement for HIV infection of renal cells since HIV-1
may enter cells by non-CD4 pathways. Infection of cultured
neural cells by HIV is inhibited by antibodies to galactosyl
ceramide but not by antibodies to CD4 [21—23]. Infection of
lymphocytic and monocytic cells is enhanced by complement
and by certain anti-HIV antibodies [24] and, therefore, it is
likely that immune cell infection in some instances may be
mediated by Fc receptor uptake of immune complexes contain-
ing HIV-l virions. This latter mechanism may be of particular
relevance to the mesangial cell.
Cultured glomerular cells have been assessed for their ability
to sustain viral replication. Glomerular epithelial cells are
resistant to infection [161, and mesangial cells are either wholly
resistant to infection [25] or able to sustain only low levels of
viral replication [16, and Kopp JB, Klotman ME, and Klotman
PE, unpublished observation]. Glomerular endothelial cells
have been reported to be highly susceptible to infection [16].
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These findings are intriguing, but must be interpreted with
caution. The protocol made use of DEAE dextran, an agent that
may have introduced virus through a mechanism other than the
physiologically relevant, receptor mediated infection. No stud-
ies have been published which examine whether renal tubular
epithelial cells can be infected with HIV. Intrinsic renal cell
types other than endothelial cells have been assessed for their
ability to sustain active viral replication. Glomerular epithelial
cells and mesangial cells, in contrast to endothelial cells, are
resistant to infection [16, 25]. Low levels of replication have
been achieved in mesangial cells in the presence of membrane
disrupting agents that bypass normal cell surface receptors and
essentially transfect the virus [16].
The studies of glomerular cell infection performed to date
have used cloned strains of HIV- I that are lymphocytotropic or
monocytotropic. It should be noted, however, that these
strains have been isolated using transformed lymphocytic or
monocytic cell lines and may have a preselected tropism.
Failure to infect a particular renal cell type in vitro, such as
glomerular epithelial cells or mesangial cells, may simply reflect
the failure to identify a strain of HIV-l that has the appropriate
cellular tropism for renal tissue. We need to know more about
the HIV-1 strains that are present in patients with HIVAN, and
in particular whether the strains share particular DNA se-
quences. If HIV-l does infect renal cells in vivo, we may only
be able to demonstrate this in vitro by devising appropriate
procedures to isolate viral strains from the kidneys of patients
with HIVAN.
In addition to the potential effects of HIV- I infection of renal
cells, various viral proteins which function in the HIV-1 life
cycle may have important stimulatory and/or toxic effects on
host cells. The viral transactivating protein Tat stimulates
proliferation of KS cells in vitro [26], and the viral surface
glycoprotein gpl2O has toxic effects on neuronal cells that are
likely mediated by calcium channel activation [27, 28]. There is
increasing evidence to suggest that HIV-1 proteins have direct
effects on renal cells. We have demonstrated that mice trans-
genic for a subgenomic, non-infectious HIV-1 DNA construct
(PNL4-3:d1443) encoding the envelope glycoproteins gp4l and
gpl2O, and accessory genes, develop a renal disease bearing a
striking clinical and histologic resemblance to the disease in
HIV-I infected patients [29, 30]. By age 300 days, approxi-
mately 40% of mice have developed nephrotic syndrome, with
edema, proteinuria, hypoalbuminemia and hypercholesterol-
emia (note added in proof). The kidneys are enlarged and show
focal segmental, and later in the disease, diffuse global glomer-
ulosclerosis. Tubulointerstitial disease is also prominent with
microcystic tubular dilation and a mononuclear interstitial
infiltrate, composed in part of macrophages (Fig. 1). HIV- 1
mRNAs are expressed in kidney, and the viral protein Rev is
present in sclerotic glomeruli. These data are consistent with a
model in which one or more HIV-l proteins trigger renal
disease, either by acting directly on renal cells, or by acting on
other cells to release soluble mediators that affect the kidney.
Cytokine dysregulation is a prominent feature of HIV- 1
infection. HIV-1 infected lymphocytes and macrophages show
increased stimulation of several peptides, including interleukins
1 and 6, tumor necrosis factor-a, granulocyte-macrophage-
colony stimulating factor, and transforming growth factor-/3 [31,
321. In some cases, intact virus is not required and gpl2O
protein is sufficient to trigger cytokine production and/or re-
lease [33]. From these studies, it has become clear that the
pathogenesis of HIVAN is complex and involves an interaction
of the host with the virus or viral gene products.
To better understand the mechanisms of HIV- 1-induced renal
disease, we must first understand the viral life cycle and the
array of viral proteins that may affect host pathogenesis. Once
integrated into the host, retroviruses behave as cellular genes in
that their regulation and pathogenesis involve interactions with
the normal host cellular machinery. In an analogous manner,
interactions of viral proteins with renal cells are likely to be
critical for the generation of HIVAN and similar mechanisms
may participate in renal diseases for which no known etiology
exists. There are obviously many steps to renal pathogenesis,
but for the purposes of this review we have focused on the
potential role that viral proteins may play in HIVAN. This is an
important area in which little effort has been devoted. In the
following sections, we describe the essential features of the
HIV-l life cycle and the gene products involved with HIV-1
replication, particularly the immediate early genes. By focusing
on those viral proteins that are known to have important host
factor interactions, we hope to stimulate research into the role
that these factors play in the pathogenesis of HIVAN.
The HIV-1 viral life cycle
HIV encodes multiple viral polypeptides (Fig. 2), structural,
enzymatic, and regulatory, that play critical roles in the viral
life cycle. Retroviruses contain three sets of genes. The gag
gene encodes the capsid antigen (p24), a myristylated protein
forming the outer shell (p17), as well as an RNA binding protein
(p9) (Fig. 3). The pol gene of HIV encodes the enzymes
protease, integrase, and reverse transcriptase. These two genes
are encoded by a single unspliced mRNA. The Pot polyprotein
is generated by a translational frame shift at the end of the Gag
polyprotein. The Gag and Gag/Pol polyproteins are then
cleaved by the viral protease into mature Gag polypeptides,
protease, reverse transcriptase, and integrase. The env gene of
HIV- 1 encodes the precursor viral envelope glycoprotein
(gpl6O) which is subsequently cleaved into its mature virion
components gpl2O and gp4l by a cellular enzyme furin [34, 35].
HIV, like other lentiviruses, contains numerous regulatory and
accessory gene products (Fig. 2). In HIV-1, these include Tat,
Rev, Nef, Vpu, Vpr, and Vif [reviewed 36—39]. The HIV
transregulatory proteins Tat and Rev play key roles in the viral
life cycle (Fig. 4). Viral gene expression is positively regulated
by the Tat protein [40, 41] while the Rev protein regulates the
composition of viral mRNA [42—44] and facilitates the trans-
port, stabilization, and translation of mRNA that contain the
Rev response element or RRE [45, 46]. Given the transregula-
tory roles of these polypeptides, it is conceivable that these
proteins also participate in the dysregulation of host gene
expression. Perturbation of extracellular matrix protein synthe-
sis and/or dysregulation of cytokines by the presence of these
viral proteins may be profoundly pathogenic to the host.
Tat and TAR
HIV-1 Tat is an 86-115 amino acid polypeptide translated
from multiply spliced RNA species containing two coding
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Fig. 2. Genomic structure of HIV illustrated
in the proviral DNA form. Long terminal
repeats (LTRs) and location of various gene
products encoded by unspliced, singly spliced,
and multiply spliced mRNAs are shown.
General functions of encoded proteins are
indicated by shading and are specifically
discussed in the text.
peptides and the structure of TAR RNA mediates binding
specificity [53]. This suggests that the preferential binding of
Tat to TAR may be, in part, due to the nature of TAR RNA; in
other words, TAR is an excellent binder of protein. Besides
mechanisms involving Tat transactivation of cellular genes,
pathogenesis might be induced by interactions of host proteins
with TAR RNA.
Functional domains of Tat
Fig. 3. Schematic diagram of the structure of HIV-1 virion. The
position of the mynstylated (p17) Gag beneath the cell surface mem-
brane is shown. The p24 Gag forms the capsid. Within the capsid is the
viral RNA, nucleic acid binding protein (p9), as well as reverse
transcriptase, protease, and integrase (not shown). The viral gpl6O is
cleaved into gpl2O and gp4l that are bound in a head to head
arrangement at the cell surface. Gp41 contains a transmembrane and
intracellular domain anchoring the envelope to the lipid membrane.
(Adapted, with permission, from American Bio-Technologies, Inc.)
exons. Tat positively regulates transcription from the viral LTR
through a mechanism that presumably involves direct or indi-
rect interaction with the TAR (Tat Activation Response) region
within the R (repeat) at the 5' end of all HIV RNAs. Tat
interactions with the HIV TAR region involve the viral pro-
moter, cellular factor(s), and the nascent RNA. Since Tat
activation does not require de novo protein synthesis [47], Tat-
induced synthesis of cellular transcription factors is not in-
volved. Tat appears to recognize the TAR element in the form
of RNA, but not DNA [reviewed 48], although the manner of
recognition appears complex, involving one or more cellular
factors. The presence or absence of key host factors that
participate in the Tat-TAR interaction could determine the
ability of various tissues to sustain viral replication. Further-
more, since the Tat-TAR interaction requires host proteins, this
complex is a strong candidate for involvement in renal patho-
genesis.
The precise mechanism of Tat activation is not well under-
stood, but appears to involve the binding of Tat, by its basic
domain, to TAR RNA. Dingwall et al [49] and Roy et a! [50]
have reported sequence specific binding of Tat protein to TAR
RNA in vitro. Studies with TAR mutants have localized the Tat
recognition sequence to the pyrimidine bulge sequence UCU,
from +23 to +25 (Fig. 5) [50—52]. This region in TAR undergoes
a conformational change upon binding to arginine containing
Tat is composed of several biologically active domains. Tat
contains seven conserved cysteine residues that are critical for
transactivation, as determined by studies with missense mu-
tants [54—56]. This region in Tat contains a metal binding motif
distinct from the two cysteine/two histidine arrangement found
in the transcription factor TFIIIA [57]. Tat contains other
functional domains as well. The carboxy-terminal region of Tat
contains a highly basic domain required for nuclear localization
and efficient transactivation [56, 58]. This domain also appears
to be important for Tat-TAR RNA interaction [50, 51, 53,
59—63]. The acidic amino-terminal region of HIV- 1 Tat is rich in
proline and is also a functional domain [56, 64—67].Analysis of
missense mutants suggests that the acidity of this region is
critical for efficient transactivation [66]. It appears that like
other known activators the structural features of the amino-
terminal region of Tat are also important for Tat mediated
transactivation [66, 68]. This domain may function through
protein-protein interaction with cellular factor(s) [661. Given
that binding and activation domains of Tat appear to be distinct
[69—71], then functionally defective mutants with binding activ-
ity might be expected to competitively reduce activity of the
wild type Tat and would, as a result, be "trans-dominant."
Since amino-terminal mutations are not trans-dominant [66, 721,
this domain may be required for stable association with a
component of the initiation or elongation complex or with a
protein that brings Tat into the vicinity of the transcriptional
apparatus. The interaction of Tat with the TATA binding protein
subunit (TBP) of transcription factor lID in vitro further suggests
a role for Tat with the basal transcription apparatus [731.
Tat and host pathogenesis
Tat protein is taken up by cells grown in culture [74].
Although the in vivo significance of this finding is not yet clear,
the potential exists for profound effects of Tat exported into
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Fig. 4. Life cycle of HI V-i . Vinons
containing two copies of positive strand viral
RNA, bind to the cell surface of target cells
by attaching to the CD4 cell surface receptor.
Fusion of the viral envelope with the cell
membrane allows entry of the nucleocapsid
into the cytoplasm. DNA is generated from
RNA by the viral reverse transcriptase and
the resultant proviral DNA is integrated into
the host genome. The provirus, once
integrated, is dependent upon the host
transcriptional machinery for RNA
expression. Once an integrated provirus is
transcribed, a low level of viral RNA is
initially produced in the early phase, which is
multiply spliced, and translated into
regulatory proteins. Once a sufficient amount
6f Tat is made, transcription from the viral
promoter increases dramatically. When the
Rev protein reaches its threshold, singly
spliced and unspliced messages are generated,
transported, and translated to the late proteins
Gag-Pol, Vpu, Env, Vif, and Vpr. Viral
maturation occurs at the cell surface
membrane and involves cleavage of the Gag-
Pol precursor into the mature structural and
enzymatic polypeptides. Viral budding occurs,
releasing the mature particles into the
extracellular space or binding and fusing with
a proximal target cell to form a syncytium.
circulation from productively infected cells or released by the
induced cytopathic effects of HIV infection. Tat may have an
additional role in the pathogenesis of AIDS by interacting with
cellular genes. Mice transgenic for the Tat gene develop dermal
tumors that bear some resemblance to KS [751. Furthermore,
recombinant Tat protein has a modest proliferative activity on
human KS derived cells in culture [261. It is not yet clear if Tat
directly stimulates KS cell proliferation, or if it acts indirectly
through perturbations of growth factors. Endothelial cells iso-
lated from the KS lesions of AIDS patients are not infected by
HIV-1 and viral nucleic acid cannot be detected by polymerase
chain reaction [26, 76, 77]. While it is conceivable that Tat
interacts directly with these cells in vivo as it is taken up by KS
cells, it is not clear whether Tat uptake is accomplished by a
specific cell surface receptor.
Within the carboxy-terminal region of HIV-l Tat is an almost
invariably conserved RGD sequence that is found in various
integrin binding extracellular matrix proteins. This region of Tat
may be involved in attachment of Tat to the cell surface [78].
Unlike HIV-l, the HIV-2 and Simian Immunodeficiency Virus
(SIV) Tat proteins do not contain an RGD motif. The signifi-
cance of this is not known, but might suggest a difference in cell
surface interactions and possibly a difference in the efficiency of
uptake. Further studies will be required using SlY and HIV-2
Tat proteins to clarify this issue. The role of the RGD motif in
the attachment of Tat remains controversial since a 90 kDa
polypeptide has been demonstrated to interact with Tat at the
cell surface by an RGD independent mechanism [79, 80].
Furthermore, the first 72 amino acids of Tat (lacking the RGD
sequence) are sufficient for uptake and transactivation [74, 81].
Presumably, more than one mechanism for Tat attachment and
uptake may exist and differences in cell type may be important.
Tat may have additional direct or indirect effects on cells that
contribute to the state of immune dysregulation in AIDS. Tat
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Fig. 5. Schematic representation of the HIV-
1 TAR and RRE elements. TAR and RRE
RNA elements interact with the HIV
transregulatory proteins Tat and Rev. TAR,
located at the 5' end of all transcripts,
contains a UCU bulge to which Tat binds in
vitro. The CUGGG motif within the TAR
bulge interacts with a host factor(s).
Presumably these host factors are required to
escort Tat into the vicinity of TAR RNA so
that Tat can augment HIV-l transcription.
The limit of the Tat activation response
element (+44) is indicated by the arrow. The
Rev response element in env RNA contains a
complex secondary structure, with multiple
stem loops indicated by roman numerals.
Stem loop II contains a high affinity binding
site for Rev, the sequence of which is shown.
(This figure has been adapted, with
permission, from [39, 163]).
Fig. 6. Schematic representation of HI V-I
LTR cis-regulatory elements and associated
host transcription factors. Unique 3' (U3),
unique 5' (US) and repeat (R) elements of the
retroviral LTR are indicated. Binding sites for
NFKB, Spi, CTF, LBP-l, NFAT, AP-l, and
TFIID (TATA) are indicated as are TFII-I and
USF which function cooperatively in the
initiation of transcription from the HIV-l LTR
[164, 165]. The TAR sequence present in the
5' region of all HIV-l transcripts is illustrated.
inhibits IL-2 and IL-2 receptor expression in Jurkat T cells [82].
Viscidi et al reported that Tat protein inhibits antigen induced T
cell proliferation in vitro [81]. Meyaard et al [831 observed a
dose dependent inhibition of T cell proliferation by CD3 mono-
clonal antibody at only high concentrations of Tat, unlikely to
be reached in vivo. Further, this inhibition was not observed in
the presence of accessory cells. No difference in response to
antigen was observed in the presence of Tat, suggesting that Tat
is probably not responsible for direct immunosuppression in
HIV infection [83]. Thus, the effect of Tat on T cell proliferation
remains controversial. Recently, AIDS patients have been
found to express elevated levels of transforming growth fac-
tor-p (TGF-f3) protein and mRNA in peripheral blood mononu-
clear cells [31]. TGF-/3 has potent antiproliferative effects on
lymphoid cells and proliferative effects on endothelial cells
[reviewed in 84]. Recently, Tat has been shown to stimulate
production of TGF-pl in bone marrow macrophages [85]. These
findings suggest a mechanism by which Tat may be involved in
the pathogenesis of AIDS by disrupting host regulatory path-
ways. Similarly, disruption of cytokine regulation by HIV-1
viral proteins may result in renal cell proliferation, toxicity, or
extracellular matrix accumulation.
Tat may alter host cellular function either by direct transac-
tivation of cellular gene transcription or indirectly by altering
cytokine and/or growth factor expression. It is conceivable that
host regulatory pathways may be altered by Tat recognition of
TAR homologous elements in cellular RNAs or through TAR
independent mechanisms which remain to be defined. Tat may
have general effects on cellular regulation by increasing the
level of transcription factor IIIC [86]. Tumor necrosis factor a
[87] and p[88] as well as IL-4 receptors [89] have been reported
to be up-regulated by the Tat gene product. In addition, Tat
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increases the levels of fibronectin, and collagen types I and HI
in glial derived cell lines [90], and HIV-l increases integrin
expression by infected T cells [91]. Dysregulation of cytokines,
matrix proteins and their receptors, and general host regulatory
pathways may profoundly affect the host. These findings
strongly suggest a role for Tat in the alterations in inflammation
and sclerosis observed in many of the HIV-associated syn-
dromes, particularly HIVAN.
In an analogous fashion to its effects on host pathways, Tat
may also directly or indirectly affect the regulation of other
copathogens. For example, human CMV expression is up-
regulated by the tat gene [92]. Similarly, the murine CMV major
immediate early promoter is transactivated by Tat [931. Tat also
transactivates the JC virus late promoter in glial cells by a
mechanism involving recognition of a TAR homologous ele-
ment [94, 95]. Transactivation by Tat in these cells appears to
be carried out by TAR dependent as well as TAR independent
mechanisms [96]. Thus, Tat may directly or indirectly alter
cellular genes as well as other viral genes that may contribute to
host pathogenesis.
Transregulation by Rev
The HIV-l Rev protein is required for the expression of
mRNAs encoding structural proteins [43, 44, 97]. Without Rev,
viral mRNAs are primarily multiply spliced (approximately 2
kb) and consist of the regulatory or "early" viral mRNAs,
including tat, rev, tev [98]Itnv [99], and nef. In the presence of
Rev, unspliced mRNAs encoding the Gag-Pol polyprotein and
singly spliced mRNAs encoding Vif, Vpr, and Env/Vpu are
exported into the cytoplasm and translated into proteins. These
late mRNAs are generated at the expense of early RNA species
and, in this way, Rev may regulate its own synthesis as well as
the synthesis of other regulatory gene products. The mecha-
nism of regulation by Rev involves recognition of a highly
structured RNA element termed the Rev Response Element
(RRE) (Fig. 5), located within env [100—111]. The interaction of
Rev with RRE facilitates transport of RRE containing singly
spliced and unspliced messages out of the nucleus and into the
cytoplasm.
Rev modulation of viral mRNA is a critical control point in
the virus life cycle (Fig. 4). Without sufficient Rev activity,
structural gene expression is insufficient for the expression of
virus [112—1 141. One attractive model for HIV-1 latency is that
quiescent cells may maintain levels of Rev below a critical
threshold. Before activation, such cell lines exhibit a Rev
deficient viral mRNA pattern [112, 113]. In the absence of
structural proteins, early events in viral replication may be
undetected by the immune surveillance system. A Rev medi-
ated shift in RNA processing enables a rapid mobilization of
structural protein synthesis directed by the pooi of previously
synthesized nuclear mRNAs.
The effects of Rev on cellular gene expression remain un-
known. It is likely that Rev can regulate one or more cellular
RNA species. Rev associates with the 110 kDa mRNA carrier
of the nuclear envelope RNA transport apparatus [115]. In this
study, Rev stimulated transport of RRE containing envelope
RNA across the nuclear pore, and at the same time inhibited
transport of mRNAs lacking the RRE. Thus, Rev may modulate
cellular gene expression by generalized repression of cellular
RNA transport. Recent evidence demonstrates that eukaryotic
Initiation Factor 5A binds to Rev and reconstitutes Rev func-
tion in Xenopus oocytes [116].
HIV-1 and Nef
The nef open reading frame is located at the 3' end of the
HIV-1 genome and encodes a protein of 25 to 27 kDa with
homology to known GTP binding proteins [117]. Nefopen
reading frame (previously referred to as "F") can be expressed
as a myristylated form associated with the inner plasma mem-
brane or as a nonmyristylated cytoplasmic form. Recently, Nef
has been reported to induce phosphorylation of a 46 kDa
protein in vitro [118], although the role of this polypeptide in
Nef function is not known. Nef protein has been described as a
negative modulator of viral gene expression [119, 120]. The
negative role of Nef in virus expression has been ascribed to its
inhibitory effects on activation of NF-KB [121], a transcription
factor that recognizes the enhancer element within the HIV-1
LTR and in a variety of cellular genes. This area remains highly
controversial. Kim et al [122] reported a lack of negative role
for Nef in virus replication. Presumably, the different published
results reflect differences in methodologies, cell lines, or viral
strains. There appear to be differences in the effects of Nef
depending on the viral isolate used and certain highly cyto-
pathic isolates resist the down-regulatory effects of Nef [123].
In contrast to the effects of Nef in vitro, SlY nef is required
for pathogenesis and the maintenance of high virus loads in
infected macaques. When injected into macaques, a nef mutant
containing a stop codon rapidly mutates to an open reading
frame in vivo [124]. While virus isolates can replicate in vitro
even with a nefstop codon, the host exerts selective pressure
on the virus to maintain of an open reading frame for nef. These
studies clearly indicate a difference in selective pressure on the
virus when grown in vitro rather than in vivo. Forexample, Nef
may play a role in vivo for evading immune surveillance. HIV-l
Nef protein has been reported to inhibit the induction of
interleukin-2 mRNA in response to T cell stimulation with
antigen [125] and to reduce the level of cell surface CD4 [126].
In transgenic animals expressing HIV- 1 Nef, reduced numbers
of CD4 positive T cells and abnormal T cell activation have
been observed [127]. Taken together, these results suggest that
the nef gene may inhibit an appropriate immune response to
viral gene expression and may contribute to the immunodefi-
ciency that is a hallmark of AIDS.
IflV-1 and Vpr
Viral protein R (Vpr) is a 96 amino acid protein (15 kDa)
encoded by an exon located between the vif and 5' tat open
reading frames [128—131]. Vpr is a transregulatory protein
capable of transactivating the HIV-1 LTR and a variety of
heterologous promoters. Although the target of Vpr is not
known, the range of Vpr action suggests that it functions
through modulation of one or more host factors. The ability of
Vpr to transactivate host promoters may induce host pathogen-
esis by dysregulating normal cellular function and altering
cytokine production. In support of this hypothesis, Vpr induces
differentiation in rhabdomyosarcoma and other tumor cell lines
[132]. The vpr gene product is important for optimal levels of
virus production as determined by comparison of wild-type and
vpr mutant viruses in culture. Vpr mutants have impaired levels
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of virus production and reduced cytopathic effects [1291. While
HIV-1 vpris not essential for virus replication [133], productive
HIV-2 infection of human macrophages requires vpr [134]. Like
the structural HIV proteins, Vpr is packaged within mature
viral particles [130, 131]. The transregulatory function of Vpr,
however, suggests a role for Vpr in early infection perhaps by
altering the intracellular environment [129, 135]. The role of
Vpr in pathogenesis remains largely unknown.
HIV-1 and Vpu
The vpu gene product [136] is encoded by a bicistronic
mRNA, also encoding Env [137]. Vpu is localized primarily to
the pennuclear cytoplasm [138]. Infection with vpu mutant
viruses leads to abnormal accumulation of viral proteins and
virions in the cytoplasm and at the cell surface [138—140]. Vpu
facilitates the efficient release of mature virions and reduces
cytopathic effects [139—142]. The mechanism of Vpu action is
not known, but Vpu may disrupt and/or prevent intracellular
CD4-gpl2O interactions [143]. For example, Vpu facilitates the
degradation of CD4 [144]. This process appears to be envelope
independent [144, 145] and can be carried out at the endoplas-
mic reticulum [144]. The disappearance of cell surface CD4
before virus release in various cell lines [146] is presumably due
to Vpu mediated CD4 degradation along with complex forma-
tion with the viral gpl2O. Vpu may have additional mechanisms
of promoting virus release, since Vpu activity is present in cells
that do not express CD4 [145]. The effects of Vpu on other cell
types such as renal cells remain unknown.
HIV-1, Vif and protease
Vif is a 23 kDa viral infectivity factor that, like vpu/env, is
encoded by a singly spliced message [130, 131]. Vii is not
contained in viral particles and is localized in the cytoplasm.
Despite this localization, Vif somehow functions to increase the
infectivity of cell-free viral particles [147—149]. The differential
requirement for vif in various cell lines [150, 151] might suggest
that some host factor(s) may supply Vii function under certain
circumstances. In CEM T cells, Vii appears to play a role in
virus maturation, rather than infectivity [152]. Sakai and co-
workers [150] have demonstrated that Vif facilitates the incor-
poration of envelope protein into virions in certain cell types.
The mechanism of Vif function may be proteolysis of HIV
envelope. Vii exhibits homology to a family of cysteine pro-
teases and it has been proposed that Vif processes gp4l [153].
Alterations in the region of gp4 I thought to be cleaved by Vif,
however, fail to inhibit the Vif effect on viral replication [151].
Cellular targets may exist for the Vif protease and these
activities may contribute to the effect of Vii on replication and
HIV pathogenesis. By analogy, the HIV protease, encoded by
pol, cleaves the cytoplasmic NF-KB precursor p105 into its
active p50 form [154]. Other cellular targets for the HIV-l
protease may include various intermediate filaments and cy-
toskeletal elements and degradation of these host proteins may
contribute to pathogenesis [155—162].
In summary, HIVAN is a relatively common complication of
HIV-1 infection, particularly in black patients. The renal man-
ifestations of this disease are striking with both glomerular and
tubular components. Increasing evidence supports a role for
HIV- 1 regulatory gene products or envelope in the pathogenesis
of this disease, acting either directly on cells, or indirectly
through host cytokine dysregulation. One of the remarkable
aspects of the HIV-l life cycle is its dependence, at critical
points, on host cellular machinery. It is this intimate relation-
ship with the host that makes HIV- 1 such a difficult pathogen to
address therapeutically. Because of the striking similarities
between HI VAN and certain forms of primary renal disease, it
is tempting to speculate that unknown retroviruses may be
responsible for several unknown primary nephropathies. A
better understanding of the interaction of HIV-1 and host cells
should provide the appropriate guidance for exploring the
pathogenesis of HIVAN and for developing effective therapeu-
tic interventions.
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